Table 2.
Statistical correlation analyses.
| A: Primary Cell Line | |||||
|---|---|---|---|---|---|
| patients | model success | p-value | |||
| n (%) | no | yes | univariate | multivariate | |
| age | 0.715 | ||||
| <61 | 54 (20.5) | 45 (83.3) | 9 (16.7) | ||
| 61–70 | 65 (24.7) | 58 (89.2) | 7 (10.8) | ||
| 71–80 | 105 (39.9) | 93 (88.6) | 12 (11.4) | ||
| >80 | 39 (14.8) | 33 (84.6) | 6 (15.4) | ||
| gender | 0.559 | ||||
| male | 159 (60.5) | 140 (88.1) | 19 (11.9) | ||
| female | 104 (39.5) | 89 (85.6) | 15 (14.4) | ||
| sample type | 0.197 | ||||
| primary | 221 (84.0) | 195 (88.2) | 26 (11.8) | ||
| metastasis | 42 (16.0) | 34 (81.0) | 8 (19.0) | ||
| localization | 0.156 | ||||
| left colon | 26 (9.9) | 23 (88.5) | 3 (11.5) | ||
| rectum | 29 (11.0) | 28 (96.6) | 1 (3.4) | ||
| right colon | 101 (38.4) | 84 (83.2) | 17 (16.8) | ||
| sigmoid | 54 (20.5) | 51 (94.4) | 3 (5.6) | ||
| transverse | 11 (4.2) | 9 (81.8) | 2 (18.2) | ||
| metastasis | 42 (16.0) | 34 (81.0) | 8 (19.0) | ||
| T | 0.778 | ||||
| T0-2 | 38 (17.4) | 34 (89.5) | 4 (10.5) | ||
| T3-4 | 181 (82.6) | 159 (87.8) | 22 (12.2) | ||
| N | 0.057 | 0.026 * | |||
| N0 | 113 (51.6) | 101 (89.4) | 12 (10.6) | ||
| N1 | 44 (20.1) | 42 (95.5) | 2 (4.5) | ||
| N2 | 62 (28.3) | 50 (80.6) | 12 (19.4) | ||
| M | 0.775 | ||||
| M0 | 165 (75.3) | 146 (88.5) | 19 (11.5) | ||
| M1 | 54 (24.7) | 47 (87.0) | 7 (13.0) | ||
| G | 0.007 ** | ||||
| G1-2 | 151 (68.9) | 139 (92.1) | 12 (7.9) | ||
| G3-4 | 68 (31.1) | 54 (79.4) | 14 (20.6) | ||
| R | 0.769 | ||||
| R0 | 172 (78.5) | 153 (89.0) | 19 (11.0) | ||
| R1 | 7 (3.2) | 6 (85.7) | 1 (14.3) | ||
| R2 | 40 (18.3) | 34 (85.0) | 6 (15.0) | ||
| L | 0.657 | ||||
| L0 | 155 (71.8) | 139 (88.0) | 17 (11.0) | ||
| L1 | 61 (28.2) | 53 (86.9) | 8 (13.1) | ||
| V | 0.769 | ||||
| V0 | 128 (59.3) | 112 (87.5) | 16 (12.5) | ||
| V1 | 82 (38.0) | 74 (90.2) | 8 (9.8) | ||
| V2 | 6 (2.7) | 5 (83.3) | 1 (16.7) | ||
| molecular type | 0.707 | ||||
| spStd | 84 (56.4) | 74 (88.1) | 10 (11.9) | ||
| spMSI-H | 25 (16.8) | 20 (80.0) | 5 (20.0) | ||
| CIMP-H | 30 (20.1) | 25 (83.3) | 5 (16.7) | ||
| Lynch | 10 (6.7) | 8 (80.0) | 2 (20.0) | ||
| UICC | 0.896 | ||||
| I | 35 (14.7) | 31 (88.6) | 4 (11.4) | ||
| II | 79 (33.2) | 71 (89.9) | 8 (10.1) | ||
| III | 65 (27.3) | 56 (86.2) | 9 (13.8) | ||
| IV | 59 (24.8) | 51 (86.4) | 8 (13.6) | ||
| MSI status | 0.297 | ||||
| MSS + MSI-L | 109 (75.7) | 95 (87.2) | 14 (12.8) | ||
| MSI-H | 35 (24.3) | 28 (80.0) | 7 (20.0) | ||
| TP53 | 0.121 | 0.105 | |||
| wt | 15 (40.5) | 13 (86.7) | 2 (13.3) | ||
| mut | 22 (59.5) | 14 (63.6) | 8 (36.4) | ||
| K-Ras | 0.248 | ||||
| wt | 106 (65.4) | 94 (88.7) | 12 (11.3) | ||
| mut | 56 (34.6) | 46 (82.1) | 10 (17.9) | ||
| B-Raf | 0.255 | ||||
| wt | 139 (85.3) | 122 (87.8) | 17 (12.2) | ||
| mut | 24 (14.7) | 19 (79.2) | 5 (20.8) | ||
| PIK3CA | |||||
| wt | 27 (100.0) | 23 (85.2) | 4 (14.8) | ||
| mut | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| B: PDX | |||||
| patients | model success | p-value | |||
| n (%) | no | yes | univariate | multivariate | |
| age | 0.048 * | ||||
| <61 | 49 (22.4) | 22 (44.9) | 27 (55.1) | ||
| 61–70 | 51 (23.3) | 16 (31.4) | 35 (68.6) | ||
| 71–80 | 78 (35.6) | 17 (21.8) | 61 (78.2) | ||
| >80 | 41 (18.7) | 15 (36.6) | 26 (63.4) | ||
| gender | 0.196 | ||||
| male | 127 (58.0) | 45 (35.4) | 82 (64.6) | ||
| female | 92 (42.0) | 25 (27.2) | 67 (72.8) | ||
| sample type | 0.014 * | 0.092 | |||
| primary | 188 (85.8) | 66 (35.1) | 122 (64.9) | ||
| metastasis | 31 (14.2) | 4 (12.9) | 27 (87.1) | ||
| localization | 0.000 *** | ||||
| left colon | 19 (8.7) | 4 (21.1) | 15 (78.9) | ||
| rectum | 32 (14.6) | 17 (53.1) | 15 (46.9) | ||
| right colon | 82 (37.4) | 20 (24.4) | 62 (75.6) | ||
| sigmoid | 43 (19.6) | 24 (55.8) | 19 (44.2) | ||
| transverse | 12 (5.5) | 1 (8.3) | 11 (91.7) | ||
| metastasis | 31 (14.2) | 4 (12.9) | 27 (87.1) | ||
| T | 0.293 | ||||
| T0-2 | 27 (14.5) | 12 (44.4) | 15 (55.6) | ||
| T3-4 | 159 (85.5) | 54 (34.0) | 105 (66.0) | ||
| N | 0.062 | ||||
| N0 | 94 (50.5) | 41 (43.6) | 53 (56.4) | ||
| N1 | 39 (21.0) | 10 (25.6) | 29 (74.4) | 0.024 * | |
| N2 | 53 (28.5) | 15 (28.3) | 38 (71.7) | 0.200 | |
| M | 0.047 * | 0.035 * | |||
| M0 | 136 (73.1) | 54 (39.7) | 82 (60.3) | ||
| M1 | 50 (26.9) | 12 (24.0) | 38 (76.0) | ||
| G | 0.083 | 0.110 | |||
| G1-2 | 123 (66.1) | 49 (39.8) | 74 (60.2) | ||
| G3-4 | 63 (33.9) | 17 (27.0) | 46 (73.0) | ||
| R | 0.074 | ||||
| R0 | 140 (75.3) | 56 (40.0) | 84 (60.0) | ||
| R1 | 7 (3.8) | 2 (28.6) | 5 (71.4) | ||
| R2 | 39 (21.0) | 8 (20.5) | 31 (79.5) | ||
| L | 0.996 | ||||
| L0 | 133 (72.3) | 47 (35.3) | 86 (64.7) | ||
| L1 | 51 (27.7) | 18 (35.3) | 33 (64.7) | ||
| V | 0.506 | ||||
| V0 | 108 (58.7) | 35 (32.4) | 73 (67.6) | ||
| V1 | 72 (39.1) | 29 (40.3) | 43 (59.7) | ||
| V2 | 4 (2.2) | 1 (25.0) | 3 (75.0) | ||
| molecular type | 0.003 ** | ||||
| spStd | 82 (53.9) | 34 (41.5) | 48 (58.5) | ||
| spMSI-H | 27 (17.8) | 3 (11.1) | 24 (88.9) | ||
| CIMP-H | 34 (22.4) | 9 (26.5) | 25 (73.5) | ||
| Lynch | 9 (5.9) | 0 (0.0) | 9 (100.0) | ||
| UICC | 0.083 | ||||
| I | 22 (11.3) | 7 (31.8) | 15 (68.2) | ||
| II | 67 (34.5) | 31 (46.3) | 36 (53.7) | ||
| III | 53 (27.3) | 16 (30.2) | 37 (69.8) | ||
| IV | 52 (26.8) | 13 (25.0) | 39 (75.0) | ||
| MSI status | 0.001 *** | 0.070 | |||
| MSS + MSI-L | 112 (76.2) | 43 (38.4) | 69 (61.6) | ||
| MSI-H | 35 (23.8) | 3 (8.6) | 32 (91.4) | ||
| TP53 | 0.887 | ||||
| wt | 21 (47.7) | 4 (19.0) | 17 (81.0) | ||
| mut | 23 (52.3) | 4 (17.4) | 19 (82.6) | ||
| K-Ras | 0.019 * | 0.005 ** | |||
| wt | 105 (64.8) | 39 (37.1) | 66 (62.9) | ||
| mut | 57 (35.2) | 11 (19.3) | 46 (80.7) | ||
| B-Raf | 0.002 ** | 0.004 ** | |||
| wt | 139 (85.3) | 49 (35.3) | 90 (64.7) | ||
| mut | 24 (14.7) | 1 (4.2) | 23 (95.8) | ||
| PIK3CA | |||||
| wt | 16 (100.0) | 4 (25.0) | 12 (75.0) | ||
| mut | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
| C: PDTM | |||||
| patients | model success | p-value | |||
| n (%) | no | yes | univariate | Multivariate | |
| age | 0.730 | ||||
| <61 | 59 (19.8) | 32 (54.2) | 27 (45.8) | ||
| 61–70 | 73 (24.5) | 36 (49.3) | 37 (50.7) | ||
| 71–80 | 115 (38.6) | 52 (45.2) | 63 (54.8) | ||
| >80 | 51 (17.1) | 25 (49.0) | 26 (51.0) | ||
| gender | 0.131 | ||||
| male | 178 (59.7) | 93 (52.2) | 85 (47.8) | ||
| female | 120 (40.3) | 52 (43.3) | 68 (56.7) | ||
| sample type | 0.150 | ||||
| primary | 254 (85.2) | 128 (50.4) | 126 (49.6) | ||
| metastasis | 44 (14.8) | 17 (38.6) | 27 (61.4) | ||
| localization | 0.011 * | ||||
| left colon | 29 (9.7) | 14 (48.3) | 15 (51.7) | ||
| rectum | 35 (11.7) | 20 (57.1) | 15 (42.9) | ||
| right colon | 117 (39.3) | 52 (44.4) | 65 (55.6) | ||
| sigmoid | 59 (19.8) | 39 (66.1) | 20 (33.9) | ||
| transverse | 14 (4.7) | 3 (21.4) | 11 (78.6) | ||
| metastasis | 44 (14.8) | 17 (38.6) | 27 (61.4) | ||
| T | 0.061 | ||||
| T0-2 | 44 (17.5) | 28 (63.6) | 16 (36.4) | ||
| T3-4 | 208 (82.5) | 100 (48.1) | 108 (51.9) | ||
| N | 0.011 * | ||||
| N0 | 133 (52.8) | 79 (59.4) | 54 (40.6) | ||
| N1 | 53 (21.0) | 24 (45.3) | 29 (54.7) | 0.046 * | |
| N2 | 66 (26.2) | 25 (37.9) | 41 (62.1) | 0.110 | |
| M | 0.008 ** | 0.070 | |||
| M0 | 191 (75.8) | 106 (55.5) | 85 (44.5) | ||
| M1 | 61 (24.2) | 22 (36.1) | 39 (63.9) | ||
| G | 0.006 ** | ||||
| G1-2 | 173 (68.7) | 98 (56.6) | 75 (43.4) | ||
| G3-4 | 79 (31.3) | 30 (38.0) | 49 (62.0) | ||
| R | 0.026 * | ||||
| R0 | 195 (77.4) | 108 (55.4) | 87 (44.6) | ||
| R1 | 8 (3.2) | 3 (37.5) | 5 (62.5) | ||
| R2 | 49 (19.4) | 17 (34.7) | 32 (65.3) | ||
| L | 0.688 | ||||
| L0 | 183 (73.5) | 94 (51.4) | 89 (48.6) | ||
| L1 | 66 (26.5) | 32 (48.5) | 34 (51.5) | ||
| V | 0.601 | ||||
| V0 | 147 (59.0) | 71 (48.3) | 76 (51.7) | ||
| V1 | 94 (37.8) | 50 (53.2) | 44 (46.8) | ||
| V2 | 8 (3.2) | 5 (62.5) | 3 (37.5) | ||
| molecular type | 0.024 * | ||||
| spStd | 93 (53.8) | 44 (47.3) | 49 (52.7) | ||
| spMSI-H | 33 (19.1) | 9 (27.3) | 24 (72.7) | ||
| CIMP-H | 37 (21.4) | 11 (29.7) | 26 (70.3) | ||
| Lynch | 10 (5.8) | 1 (10.0) | 9 (90.0) | ||
| UICC | 0.023* | ||||
| I | 40 (14.8) | 24 (60.0) | 16 (40.0) | ||
| II | 93 (34.3) | 57 (61.3) | 36 (38.7) | ||
| III | 72 (26.6) | 33 (45.8) | 39 (54.2) | ||
| IV | 66 (24.4) | 26 (39.4) | 40 (60.6) | ||
| MSI status | 0.019 * | 0.070 | |||
| MSS + MSI-L | 127 (75.1) | 56 (44.1) | 71 (55.9) | ||
| MSI-H | 42 (24.9) | 10 (23.8) | 32 (76.2) | ||
| TP53 | 0.786 | ||||
| wt | 21 (45.7) | 4 (19.0) | 17 (81.0) | ||
| mut | 25 (54.9) | 4 (16.0) | 21 (84.0) | ||
| K-Ras | 0.014 * | 0.002 ** | |||
| wt | 123 (65.1) | 56 (45.5) | 67 (54.5) | ||
| mut | 66 (34.9) | 18 (27.3) | 48 (72.7) | ||
| B-Raf | 0.022 * | 0.026 * | |||
| wt | 162 (84.8) | 70 (43.2) | 92 (56.8) | ||
| mut | 29 (15.2) | 6 (20.7) | 23 (79.3) | ||
| PIK3CA | |||||
| wt | 28 (100.0) | 16 (57.1) | 12 (42.9) | ||
| mut | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
Statistical analysis for correlations of model establishment success with clinicopathological for A: primary cell lines, B: PDX, and C: patient-derived tumor model (PDTM). Analysis were performed using a univariate (chi-squared-test and Fisher exact test) and multivariate approaches. The multivariate analysis was done including all significant parameters. * = p <0.05, ** = p < 0.01, *** = p < 0.001.